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Introduction

Results

Results

Proton pump inhibitors are commonly prescribed medications for children.
Current dosing of proton pump inhibitors (PPIs) relies on weight-based
strategies (e.g., mg/kg, weight-tiered). Such dose selection may not be
appropriate for obese children, as it could result in over- or under-dosing with
subsequent toxicities (i.e., infection, osteopenia) or treatment failure. Since
obese children are 6-times more likely to suffer from gastroesophageal reflux
disease, and PPIs have become some of the most commonly prescribed
drugs to children, there is a critical need to characterize the drivers of
variability in systemic exposure to PPIs, other than pharmacogenetic (i.e.,
CYP2C19 genotype), for obese children.

Figure 2. Time-course of pantoprazole (PAN) plasma concentrations.
Following oral administration of a single dose pantoprazole, a total of 546
plasma samples were collected at designated time points from 57 subjects.

Figure 3.
Comparison of
observed and
population
predicted PAN
concentrations. The
popPK model
generally
overpredicted PAN
concentrations
(RMSE = 194%). The
overprediction is
mostly noticed at
higher concentrations.

Objective
We previously developed a population pharmacokinetic (popPK) model of
pantoprazole (PAN) for obese children. Our objective was to evaluate the
predictive performance of this model in an independent cohort or normal
weight, overweight and obese children.

Figure 4. PAN predicted /
observed AUC ratios
stratified by weight
category. The AUC ratios
were not significantly different
among normal, overweight
and obese groups (2.2 vs. 1.7
vs. 15, p=0.06); however, a
trend toward a better model
prediction is seen in obese
children.

Methods
Figure 1. Approach to Evaluation of a Population Pharmacokinetic
(popPK) Model.

Step 1: popPK
model development
in a clinical
pharmacokinetic
study

Step 2: A separate
clinical
pharmacokinetic
study is conducted

Step 3: - Evaluation:
Model predicted
concentrations - are they
in agreement with
observed drug
concentrations (from
study in Step 2)?

Details on prospective evaluation of a popPK model (Step 3).
• Identify model structure: 2-compartment structural model with modified first-order
absorption (ka=7.3 hr-1)
• Collect typical population parameters and covariate relationships. Covariates
identified to affect PAN PK are weight and CYP2C19 genotype.
• Predict PAN PK. Predictions are based on dose, sampling times, and covariates
from 57 children.
• Assess general model predictive performance: visually and by relative root mean
squared error (RMSE)
• Assess model performance by weight category: by ratio of predicted-to-observed
area under the concentration time curve (AUC)

Table 1. Drug formulation and patient demographics from a published
popPK study and CMH cohort. In both studies, children were enrolled
prospectively and received a single oral dose of pantoprazole based on their
respective lean body weight. CYP2C19 phenotype was assigned according
to the characterized genotypes of each subject: Intermediate metabolizer
(IM): CYP2C19*1*2 or *2*17; Normal metabolizer (NM): CYP2C19*1*1 or
*1*17.
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Drug formulation
Number of patients
(M/F)
Age range (yr)
Weight category

Weight range (kg)
BMI range
CYP2C19 phenotype

Published popPK study
PAN delayed release
N=40 (18/22)
6-17
Obese (n=40)

32.4-131.6
22.1-42.0
IM=18
NM=21

CMH cohort
PAN immediate
release
N=57 (24/33)
6-17
Normal (n=29),
Overweight (n=16),
Obese (n=12)
18.5-124
15-41.72
IM=13
NM=44

Conclusions
• Overprediction of observed PAN concentrations may be due to differences
in PAN formulation (delayed vs. immediate release) between studies.
• Ongoing study of a delayed release PAN will asses formulation effect,
which will allow further refinement of existing popPK model.
• Our ultimate goal is to identify appropriate dosing strategy for PAN and
other PPIs to prevent over- or under-dosing..
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